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Abbreviations 
 
AC:              Abdominal circumference 
cAMP:  Cyclic adenosine monophosphate 
ADA:     American Diabetes Association 
AIR:       Acute insulin response 
ALP:      Alkaline phosphatase 
ALT:      Alanine aminotransferase 
AST:     Aspartate aminotransferase 
ATP:  Adult Treatment Panel 
AUC:     Area under the curve 
BCF:    Beta cell function 
BFP:      Body fat percent 
BMD:    Bone mineral density 
BMI:     Body mass index 
CI:         Confidence interval 
CV:       Coefficient of variations 
DEXA:  Dual-energy X-ray absorptiometry 
DI:         Disposition index 
FBG:     Fasting plasma glucose 
FFA:      Free fatty acid 
FSH:       Follicular stimulating hormone 
GGT:      Gamma-glutamyl transferase 
GI:          Glucose intolerant 
GIR:     Glucose infusion rate 
HbA1c:   Hemoglobin A1c 
HDL:      High density lipoprotein 
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HIRI:     Hepatic insulin resistance index 
HOMA:  Homeostatic Model Assessment  
IFCC:     International Federation of Clinical Chemistry 
IFG:       Impaired fasting glucose 
IGI:        Insulogenic index 
IGT:       Impaired glucose tolerance 
IL-6:       Interleukin-6 
IR:         Insulin resistance 
IS:           Insulin sensitivity 
ISICederholm: Cederholm’s insulin sensitivity index 
ISIcomp:    Composite insulin sensitivity index 
ISIest:      Estimated insulin sensitivity index 
IVGTT:   Intravenous glucose tolerance test 
LDL:       Low density lipoprotein 
MAD:       Median absolute deviation 
MCRest:   Estimated metabolic clearance rate 
NAFLD:   Non-alcoholic fatty liver disease 
NGT:        Normal glucose tolerance 
OCN:        Osteocalcin 
OGIS:        Oral Glucose Insulin Sensitivity 
OGTT:      Oral glucose tolerance test 
OR:            Odds ratio 
OPG:          Osteoprotegerin 
P1NP:       Procollagen type 1 amino-terminal propeptide  
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RANKL:     Soluble receptor activator NF-kB ligand 
RR_Dias:    Diastolic blood pressure 
SD:                Standard deviation 
SHBG:           Sex hormone binding protein 
T1DM:             Type 1 diabetes mellitus 
T2DM:          Type 2 diabetes mellitus 
TNF-α:          Tumor necrosis factor - alpha 
VLDL:          Very low density lipoprotein 
WHO :          World Health Organization 
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1. Introduction and aims of our study 
 
Major challenges of the 21
st
 century health care of the developed world include type 2 
diabetes mellitus (T2DM) and the bone loss epidemic. The parallel increase of the two 
diseases poses some contradiction. Both are associated with body weight, however increasing 
obesity and insulin resistance have a causal role in the pathogenesis of T2DM. Conversely, in 
osteoporosis the higher body fat content has a bone protecting effect. Type 1 diabetic patients 
have decreased bone mineral density (BMD) and increased fracture risk while in T2DM this 
association is less strong, data exist about both increased or decreased BDM in T2DM 
patients [1, 2].  
In order to investigate the relationship between insulin resistance (IR) or insulin 
sensitivity (IS) and other diseases / symptoms, like osteopenia and osteoporosis that may be 
associated with insulin resistance we need an easily accessible simple IR measuring method 
that is cheap, can be used in a large number of patients, reproducible and is validated via 
more sophisticated studies. Precise measurement of IR is also important for the prevention, 
diagnosis and the therapeutic follow up of T2DM. For measuring IS, today the “gold 
standard” is still the “hyperinsulinemic normoglycemic clamp” developed by DeFronzo et al. 
[3]. However, it is an expensive and time consuming method which cannot be used in a large 
number of patients in clinical setting, so there have been a number of attempts to develop 
methods replacing the clamp, e.g. the Homeostasis Model Assessment (HOMA) indices 
which use data from fasting blood samples, or so are a number of indices derived from the 
oral glucose tolerance test (OGTT). 
The first part of my work deals with the diagnostic evaluation of IS in terms of simple 
fasting and OGTT derived indices which still seem to be a hurdle in IS estimation since the 
most widely used HOMA indices in clinical practice do not correlate well with the gold 
standard clamp methods. We aimed to gain further insights into the pathophysiology and 
diagnosis of IR and related complications by studying the association between transaminase 
levels and clamp measured insulin sensitivity, moreover we sought to explore a unique side 
of the gender specific aspect of insulin homeostasis / energy metabolism, with special regard 
on the non-alcoholic fatty liver disease (NAFLD) which is one of the major link between 
insulin resistance and cardiovascular disease. By exploring the pathophysiology of the IR 
related steatohepatosis often associated with the ‘unexplained’ elevation of transaminase 
levels in overweight insulin resistant / T2DM patients, we might be able to improve the value 
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of the HOMA model with no extra costs, although possible gender related differences will 
have to be taken into account. 
 To explore the relationship between T2DM / IR and bone homeostasis first we 
analyzed data from a large epidemiological study which included the screening results of 
more than 6000 people at Balaton Upper-lands. Based on the results of this epidemiological 
study, we conducted a cross over analysis on our existing clamp database where we measured 
markers of bone turnover, i.e. total non-carboxylated osteocalcin (OCN) levels and other 
metabolic-hormonal factors, like adipocytokines, lipids, lipoproteins, sex hormones.  
Previous human studies have shown that serum OCN concentration is negatively associated 
with the plasma glucose level and body fat mass [4-7] and positively associated with insulin 
secretion [8, 9], lower insulin resistance [5, 6, 10] and higher serum adiponectin 
concentration [4, 10]. In most of this work, the HOMA model has mainly been used to assess 
β-cell function, insulin sensitivity and the involvement of OCN on glucose metabolism, 
although we and others [11] have shown that fasting indices do not always correlate well with 
the real insulin resistance, therefore insulin sensitivity was measured by the gold standard 
clamp method. Recently, it has been demonstrated that osteoblasts are able to induce 
testosterone production by the testes, though they fail to influence estrogen production by the 
ovaries [12]. The role of testosterone in the bone–energy homeostasis is presumably gender-
specific, as the effects of OCN were only demonstrated in Leydig cells and not in the ovaries; 
moreover, low testosterone levels are only associated with a metabolic syndrome in men [13]. 
 
Based on previous data and our preliminary assumptions discussed above our main 
goals were: 
1. To explore the diagnostic value of the most frequently used simple fasting and OGTT 
derived insulin sensitivity indices compared to the gold standard clamp method. 
2. To try to justify possible new approaches / directions in the simple diagnostics of insulin 
resistance. 
3. To explore epidemiological characteristics of the relationship between bone loss and 
diabetes / insulin resistance. 
4. To explore molecular background of the bone – energy homeostasis axis, by analyzing 
the associations between clamp measured insulin sensitivity, total-OCN and other metabolic 
biomarkers. 
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5.  Since our previous data suggested that basic sex differences exist in the pathogenesis and 
manifestations of insulin resistance and associated diseases, male and female populations 
were separately analyzed in most of our studies to address this issue. 
2. Patients and methods - General considerations 
 
2. 1. Epidemiologic study 
 
In our study we have analyzed the results of general screening tests of the adult 
population in Balaton Upper-lands which was performed between 2003 and 2006. Screenings 
were done on a voluntary basis advertised as primarily bone density screening measurements 
in local surgeries or at working places (Offices, Factories). Since the screening examinations 
involved bone density measurements / osteopoporosis screening, there were more women 
than men who attended the screenings.  
During screening examinations anthropometric assessments (body weight and height, 
abdominal circumference [AC]), sitting blood pressure (Omron 705CP digital equipment), 
blood sugar (Personal DCont and Optimum, 77 Electronics, Hungary), total cholesterol 
measurements (Accutrend GCT 1537962 and Accutrend GC 1418246, Roche, Germany) 
from capillary blood and calcaneus bone ultrasound density ultrasound measurements (GE-
Lunar, Achilles Plus, USA) were carried out. Questions about medical history, concomitant 
medications and life style were also raised. Screenings were not done always in fasting state 
although data were available about the time of last meal besides previous concomitant 
treatment for diabetes.  We have analyzed the following data: sex, age, systolic and diastolic 
blood pressure, plasma glucose, total-cholesterol, AC, BMI and T score calculated by the 
calcaneus ultrasound density data of young and healthy population of the same sex. 
Based on available data and the results of the screening examinations we defined certain 
diseases / syndromes to be present in the population, like diabetes, hypertension, metabolic 
syndrome, osteopenia and osteoporosis. ‘Bone density’ measured by ultrasound is not 
identical to BMD measured by ‘dual-energy X-ray absorptiometry’ (DEXA), due to the  
effect of bone structure, albeit they are closely associated and as such it is widely accepted in 
both the diagnosis and the follow up of osteoporotic treatment [14]. Data were analyzed by 
sex and age groups. 
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2.2. Clamp studies 
2.2.1. OGTT, IVGTT and clamp 
 
All clamp studies were carried out after receiving signed informed consents from the 
subjects. Study was approved by the Hungarian Central Ethical Committee (A12988-2/2003-
1018-EKU, ad.8-311/2009-1018EKU). Patients and healthy volunteers were recruited from 
our own diabetes outpatient clinic and by referral from regional primary care physicians. All 
subjects underwent a standard 75 mg oral glucose tolerance test (OGTT) which determined 
the subject’s basal glucose tolerance (i.e. normal or impaired glucose tolerance, impaired 
fasting glucose or T2DM) during the screening period. Within 3 weeks after the OGTT 
patients were hospitalized for the clamp. Subjects fasted on the night prior to the clamp 
examination. They first underwent an intravenous glucose tolerance testing (IVGTT) to 
assess insulin secretion (0.3g/body weight kg iv. glucose injection). Following the IVGTT, a 
hyperinsulinaemic normoglycaemic clamp examination was carried out, as described by 
DeFronzo et al. [3]. During a continuous infusion of insulin (45 mU × min × m−2) and 
glucose (20 %), the steady state was set at the constant glucose infusion rate (earliest from the 
120
th
 minute of clamp), where blood sugar level stayed between 5.0 and 5.9 mM / l for at 
least 30 min after the beginning of steady state. Glucose and insulin levels were measured 
from venous blood at 0-, 3-, 5-, 10-, 20-, 30-, 40-, 50
th
- and 60
th
  min samples of IVGTT, 
before the beginning, and at the 0-, 10- 20-, 30
th
 min samples of the steady state of clamp. 
Insulin secretion was determined from IVGTT by the insulogenic index [IGI = Δ (insulin5’-
insulin3’) / Δ (glucose5’-glucose3’)] and the acute insulin response [AIR = (insulin5’ + 
insulin3’) / 2 – insulin0’)], both being sensitive indicators of the first phase insulin response, 
and hence the real beta cell function. For the liver function test – IS relationship study hepatic 
insulin resistance index (HIRI) was estimated from the OGTT 0
th
 and 30
th
 min glucose and 
insulin values [HIRI = (GLU-AUC0-30’) × (Ins-AUC0-30’)] described by Muhammad et al. 
[15].  Glucose and insulin area under the curve (AUC) values were calculated using the 
trapezoidal rule, both from OGTT and IVGTT. We used lean body (= muscle)-adjusted 
glucose uptake (M3 value, mg/min/kg) calculated from the glucose infusion rates during 
clamp, to measure peripheral (muscle) glucose utilization rates. Formula for calculation of 
serum glucose levels from mmol/l to mg/dl for the clamp M3 value: mg/dl = 18×mmol/l. 
Body composition was determined by dual-energy X-ray absorptiometry (DPXMD+, GE-
Lunar, USA, Florida). In the insulin sensitivity diagnostic evaluation study we used fasting 
and OGTT derived insulin sensitivity indices. 
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2.2.2. Calculations of insulin sensitivity indices 
 
2.2.2.1. Data derived from the clamp examinations [3]  
Glucose infusion rate (GIR),(mg x kg
-1
 x min
-1
): the glucose infusion rate necessary to keep a 
steady state between the 120
th
 and 150
th
 minutes of the clamp. 
M1: whole body glucose uptake (mg x kg
-1
x min
-1
) 
M2: glucose uptake adjusted for body surface (mg x m
-2
 x min
-1
) 
M3: glucose uptake adjusted for lean body (muscle) mass (mg x kg muscle
-1
 x min
-1
) 
For clamp indices we used the whole body glucose uptake (M1) and muscle mass adjusted 
glucose uptake (M3) to evaluate the individual OGTT / IVGTT derived IS indices. 
 
2.2.2.2. OGTT insulin sensitivity indices 
 
MCRest (Estimated Metabolic Clearance Rate by Stumvoll) = 18.8 - 0.271 x BMI - 0.0052 x 
Ins120- 0.27 x Glucose90 (ml x kg 
-1
x min 
-1
),  
where Ins120 is the 120
th
 minute insulin level, and Gluc90 is the 90
th
 minute glucose level of 
the OGTT [16]. 
ISIcederholm = {75.000 + (Gluc0 –Gluc120) x 1.15 x 180 x  0.19 x kg-bodyweight}                                                  
(120 x log(Insm) x Glucm)                                                                                
(ml x kg
-1
 x min
-1
), where  Gluc0 is the basal, Gluc120 is the 120
th
 minute, Glucm is the mean 
of all OGTT glucose levels, and  Insm is the mean of all OGTT insulin levels [17]. 
ISIest (Estimated Insulin Sensitivity Index) = 0.226 - 0.0032 x BMI- 0.0000645 x Ins120 – 
0.0037 x Gluc90  
(umol x kg 
-1
x min 
-1
x pM 
-1
), where Ins120 is the 120
th
 minute insulin level, Gluc90 is the 90
th
 
minute glucose level of the OGTT [16]. 
OGIS = f(G0,G90,G120,I0,I90,D0), is a function of the 0
th
, 90
th
, 120
th
 minutes glucose levels and 
the 0
th
, 90
th
 minute insulin levels of the OGTT (ml x min 
-1
 x m 
-2
), calculated by the OGIS 
calculator accessible from  http://webmet.pd.cnr.it/ogis/ogis.php where D is the glucose dose 
employed [18]. 
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ISIcomp (Composite Insulin Sensitivity Index, Matsuda) =  10.0000                                    ,       
                                                                                 √ (Gluc0 x Ins0 x Glucm x Insm)  
where Gluc0 is the 0
th
 minute glucose, Glucm is the mean of all OGTT glucose levels,  Ins0 is 
the 0
th
 minute insulin,  Insm is the mean of all OGTT insulin levels [19]. 
 
2.2.2.3. Fasting indices 
 
HOMA (Homeostasis Model Assessment) [20]: 
HOMA-R (for insulin resistance) = Go x Io / 22.5, (HOMA-1), where Go is the basal glucose 
level (mM/L),   Io is the basal insulin level (uU/ml). 
HOMA-S (for insulin sensitivity) = 1/ HOMA-R  
QUICKI = 1 / {log (Io) + log (G o)}
 
(logarithmic transformation of HOMA) [21]. 
HOMA-B (for insulin release) = I0 x 20 / (Gluc0 - 3.5) 
HOMA-S% and B% (HOMA-2): indices of insulin sensitivity (S%) and beta cell 
function(B%), calculated by the HOMA calculator V2.2 from the 0
th
 minute IVGTT samples, 
downloaded from https://www.dtu.ox.ac.uk/homacalculator (‘the Oxford Model’) [22, 23]. 
FFA-QUICKI = 1 / {log (Io) + log (Go) + log (FFAo)}, where G0 is the basal glucose, I0 is the 
basal insulin, FFA is the basal fatty acid levels (mmol/l) [24]. 
 
2.2.3. Biochemical measurements 
 
Routine biochemical parameters were measured on Cobas Mira and Hitachi 912 
laboratory automats with the same method (according to IFCC recommendations) during the 
recruitment period (2003 – 2008). Reference ranges, detection limits and test principles were 
unchanged during this test period. Alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), 
serum bilirubin, free fatty acid (FFA), insulin, glucose, HbA1c levels and conventional lipid 
parameters were determined using Roche reagents (Roche Diagnostics, Germany). HbA1c 
levels were measured by the IFCC reference method. Total (non-carboxylated) OCN, 
estradiol, testosterone, follicular stimulating hormone (FSH) and serum insulin levels were 
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measured with an Elecsys 2010 electrochemiluminescense automat (Roche Diagnostic, 
Germany). Coefficient of variation (CV) for osteocalcin test varies between 1.8 and 6.5% 
respectively for the kits used in our study. Serum leptin, adiponectin, interleukin-6 (IL-6) and 
tumor necrosis factor-α (TNF-α) levels were measured by the enzyme-linked immunosorbent 
method (Quantikine DLP00, Quantikine DRP300, Quantikine HS600B and Quantikine 
HSTA00D kits respectively;  R&D Systems, Minneapolis, MN, USA). Lipid fractionation 
was done by the Lipoprint System® Quantimetrix, USA). Lipid subfractions (very low 
density lipoproteins [VLDL], intermediate-density lipoproteins [IDL-A, −B and –C], and 
low-density lipoproteins [LDL1−4 subfractions, LDL 2–4 subfractions = small-dense LDL]), 
total LDL and high-density lipoprotein [HDL] were separated by acrylamide gel 
electrophoresis. 
 
2.2.4. Statistics 
2.2.4.1. Epidemiological study 
 
Data analysis for the epidemiologic study was carried out with an SPSS 10.0 Program 
(Statistics for Windows). Numeric data were indicated as mean and standard deviations. 
Mean data between the groups were compared with two-sided tests. For comparing disease 
prevalence within groups of different genders and ages we used the χ2 test (in small sample 
numbers χ2 was calculated by continuity correction), additionally we have applied the Fisher 
test. Significance level was considered at p < 0.05 values, with indicating odds ratios (OR) 
and 95% confidence intervals (CI). The relationships between T score and the individual 
metabolic parameters were analyzed by bivariate correlations (Pearson).  
 
2.2.4.2. Evaluation of fasting and OGTT indices 
Coefficients of variations of fasting and OGTT indices were calculated according to the 
equation CV = (SD / √2) x 100/¥ , where SD is the standard deviation of the intra-subject 
changes of indices, and ¥ is the mean of all values. For evaluating the simple insulin 
sensitivity indices we used a score system to evaluate the individual indices and all of the 
fasting or OGTT indices within the groups divided by several aspects (Table 1.). It 
determined the value of the indices based on the correlation coefficients and their 
significance levels between the M1 and the specific index. We considered 12 to be the 
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maximum points (100%) within each group (r = 0.8-1.0 very strong correlation, p < 0.001), 
the final score was given by the percent calculated from the ratio of the reached and 
maximum scores.  
 
Points Correlation coefficient    p points Correlation 
coefficients 
p 
12  Very strong (0.8-1.0) < 0.001 5 Moderate < 0.05 
11 Strong  (0.6-0.79) < 0.001 4 Weak (0.2-0.39) < 0.001 
10 Strong < 0.01 3 Weak < 0.01 
9 Strong < 0.02 2 Weak < 0.02 
8 Moderate  (0.4-0.59)              < 0.001 1 Weak < 0.05 
7 Moderate < 0.01 0   
6 Moderate < 0.02    
 
Table 1.: Score system used for the evaluation of IS indices. The final score (%) is the 
ratio of the reached and maximum scores multiplied by 100.  
 
When calculating sensitivity and specificity, values of the “gold standard” parameters under 
25 percentile (M1 for IS) were considered to be the abnormal range (“real” IR), namely the 
“worst” quartiles: 
 
Sensitivity (%) = Number of real (M) IR cases – number of false negative cases    x 100                            
number of real (M) IR cases 
 
Specificity (%) = Number of real (M) IS cases – number of false positive cases  x 100                         
number of real (M) IS cases 
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2.2.4.3. General statistical considerations in clamp studies 
 
All statistical analyses were performed with R Statistical Software (version 2.15.0). 
Data points are expressed as mean ± standard deviation, if data were not normally distributed 
we used mean, standard deviation, median and mean absolute deviation (MAD) for each 
value presented The Wilcoxon test (or in case of normally distributed parameters two-sided T 
test) were used to assess group differences. Spearman's correlation coefficients were 
calculated to test the association between biochemical and other variables, since non-linearity 
characterized these associations. Partial correlation coefficients were used to assess the 
influence of possible confounding factors such as age, body mass index (BMI), body fat 
percent (BFP),  HbA1c levels (as being a mixed diabetic and non-diabetic population), 
genetic predisposition. Further adjustment with adiponectin and FSH in females and 
testosterone in males was used in the OCN - clamp study to exclude the effect of menopausal 
state in women, and the possible role of adiponectin / testosterone in mediating the metabolic 
effects of OCN in males/females. A p value of < 0.05 was considered significant. 
Sample size determination was done empirically based on other clamp studies in the 
original protocol. For the liver – IR analysis we have used boot strap analysis (Monte-Carlo 
simulation) to test the minimal sample number to determine statistical differences between 
groups.  
 
Feature selection analysis (Boruta algorithm) was used to find the most important 
attributes that are related to the M3 value in all of our clamp studies. This algorithm is a 
wrapper built around the randomForest classification algorithm (implemented in the R 
package randomForest) [25]. The randomForest algorithm is an ensemble approach (divide 
and conquer approach); it grows many decision trees and it gives a numerical estimate of the 
importance of a feature. A Z score is used as the importance measure since it takes into 
account the fluctuations of the mean accuracy loss among trees in the forest. To avoid 
random fluctuations in determining the importance of any given attribute, a reference set of 
‘shadow attributes’ is used for deciding which attributes are truly important, since the 
importance of a shadow attribute can be non-zero only due to random fluctuations [26].  
Multiple regression analysis was used in the NAFLD - IR study in men and women in 
order to determine the ability of metabolic parameters selected as ‘important attributes’ by 
feature selection analysis to predict clamp measured insulin sensitivity: 
13 
 
Model for women: y~b0 + b1x1 + b2x2 +…+ b5x5, where response variable y is M3, and 
explanatory variables x1, …, x5 are BMI, AC, insulin, fasting FFA, ALT, respectively and 
coefficients are in Table 6. The intercept b0 is the expected mean value of M3 when all xi = 
0. 
Model for men: y~b0 + b1x1 + b2x2 +…+ b9x9, where response variable y is M3, and 
explanatory variables x1, …, x9 are AC, leptin, BMI, insulin, TG, FFA, glucose, diastolic 
blood pressure (RR_Dias) and age, respectively and coefficients b1…b9 are in Table 7. The 
intercept b0 is the expected mean value of M3 when all xi = 0. 
 
2.2.5. Ethical considerations  
 
For the epidemiological study we used database of an adult population screening 
between 2003 and 2006 in Balaton Upper-lands, all screenings approved by the local 
Hungarian Public Health and Medical Officer Service. Screenings were carried out on a 
voluntary basis, most of them were advertised as general screening assessments at General 
Practitioners’ outpatient clinics, some of them were screening examinations taken place at 
working environment (Factories and Offices).  
For clamp studies, data were retrospectively analyzed from a scientific study 
approved by the Hungarian Central Ethical Committee (A12988-2/2003-1018-EKU and ad.8-
311/2009-1018EKU) titled ”Diagnostic investigation for the early recognition of insulin 
resistance syndrome and its complications” (granted by Hungarian National Research and 
Innovation Program: NKFB -1B/0007/2002) and “Development and application of protein 
microarray technics to characterize insulin resistance syndrome and autoimmune processes” 
(granted by KMOP-1.1.1-08/1-2008-0028 ).  
Recruitment started in 2004 and ended in 2010. After obtaining signed informed 
consent, in total 306 IVGTTs were carried out followed by a normoglycemic 
hyperinsulinemic clamp. Subjects were classified as having normal / impaired glucose 
tolerance or type 2 diabetes based on a standard 75 g OGTT at screening. All details about 
medical history, concomitant medications and life style were available for the data analysis.  
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3. Results  
3.1. Diagnostic evaluation of simple insulin sensitivity indices 
3.1.1. Study population 
 
We performed OGTT examinations on 317 subjects during the screening period. 
(From the OGTT samples we determined glucose and insulin levels). Patients were 
categorized according to the ADA criteria (normal glucose tolerance (NGT): fasting plasma 
glucose (FBG) < 5.6 mM/l, impaired fasting glucose (IFG): FBG 5.6 – 6.99 mM/l, impaired 
glucose tolerance (IGT): FBG < 7.0 mM/l and 120
th
 minute glucose: 7.77 – 11.0 mM/l, 
T2DM: fasting glucose ≥ 7.0 mM/l, and/or 120th minute ≥ 11.1 mM/l) [27]. Those, taking any 
antidiabetic medications, were treated for hormonal disease or received hormone substitution, 
were excluded from the study. Baseline characteristics of the subjects are listed in Table 2.  
 
 
 
 
 N m f age BMI 
(kg/m
2
) 
HbA1c 
(%) 
M1  
(mg/minxkg
-1
) 
AIR 
(uE/ml) 
         
NGT 45 25 20 40.02±15.07 28.37±6.82 5.53±0.82 11.29±4.87 55.61±49.15 
IFG/IGT 67 29 38 49.13±9.24* 30.85±5.21* 6.02±0.74* 8.37±3.26* 28.07±31.56* 
DM 24 11 13 52.66±5.63* 32.13±6.10* 6.48±0.88* 6.46±3.38* 14.24±24.18* 
 
Table 2.: Basic characteristics of the examined population. *: Significant (p < 0.05) 
difference compared to the NGT group, N: number of subjects m: number of males, f: number of 
females, M1: whole body glucose uptake, AIR: acute insulin response of IVGTT, BMI: body mass 
index, HbA1c: Hemoglobin A1c, NGT: normal glucose tolerant, IFG: impaired fasting 
glucose, IGT: impaired glucose tolerant, DM: diabetic subjects 
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3.1.2. Diagnostic evaluation of simple fasting and OGTT derived insulin sensitivity 
indices 
The cumulative evaluation is shown on Figures 1. and 2. based on the earlier 
described score system (Table 2.). Most of the fasting indices show moderate (R = 0.4-0.6) 
correlation with M1 within most groups (correlation matrix not shown here). There was no 
significant correlation between fasting indices derived from the OGTT basal samples and M1 
in the elder (age above median), normal glucose tolerant (NGT), and less severe (HbA1c 
under median) glucose intolerant groups. No correlation found in the elder NGT group 
between fasting indices derived from the mean of OGTT and IVGTT basal samples and M1. 
In HOMA-2 model we only found good correlations (r = 0.6-0.8) in the young NGT, diabetic 
and male groups.  Cumulative evaluation of the fasting and OGTT derived indices based on 
group subanalyses are shown on Figure 3. and Figure 4. The sensitivity of fasting indices 
(average 50.4 ± 4.6%) is low, while their specificity (83.3 ± 1.6%) is high, i.e. there are a 
relatively large number of false negative but less of false positive cases (Table 3.). 
 
 Mean  of 
fasting  IS 
indices 
Maximum 
value 
(HOMAigtt) 
Mean  of 
OGTT  IS 
indices 
Maximum 
value 
(ISIcederh, 
ISIest) 
 
Sensitivity 
 
50.92±4.43% 
 
 
  58.82% 
 
60.25±8.06% 
 
  66.6% 
Specificity 83.56±1.79%    85.7% 87.29± .87%   89.1% 
 
Table 3.: Mean sensitivity and specificity of IS indices, considering the 25 percentile of 
M1 values as the cut-off for “insulin resistant” and  “insulin sensitive” (less insulin 
resistant) groups. IS: Insulin sensitivity, HOMAigtt: HOMA index from IVGTT 0
th
 minute 
glucose and insulin values, OGTT: oral glucose tolerance test, ISIcederh: Cederholm’s IS 
index, ISIest: estimated Stumvoll’s IS index.  
 
ISIcederholm , MCRest, and ISIest, including body weight in their equations, derived from 
the OGTT, show the strongest correlations with M (r > 0.6 correlations in most groups). On 
Figure 3. and Figure 4. it is clearly shown that all OGTT indices show better cumulative 
score than the average (mean of 0
th
 minute OGTT and IVGTT insulin and glucose values) of 
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fasting indices. The only non-significant correlation was observed with the Matsuda equation 
(ISIcomp) in the young NGT group. The mean sensitivity and specificity of OGTT indices 
were higher than that of the HOMA model (60.2 ± 8.0%, and 87.2 ± 1.8% respectively, Table 
3.). 
 
Figure 1.: Evaluation of  fasting IS indices calculated from the 0
th
 minute OGTT and 
IGTT values and the mean of these values, based on the correlation coefficients and 
significance levels with M1. “OGTT”: indices derived from 0th minute OGTT samples, 
“IGTT”: indices derived from 0th minute IVGTT samples, “a”: indices derived from the 
average of the two samples. 
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Figure 2.: Evaluation of the individual OGTT indices based on the correlation 
coefficients and significance levels with M1  in different subgroups. The mean evaluation 
of fasting indices is also indicated on the right side of the graph. ISIcomp: Composite insulin 
sensitivity index (Matsuda), ISICederholm: Cederholm’s insulin sensitivity index, MCRest: 
estimated metabolic clearance rate (Stumvoll), OGIS: Oral Glucose Insulin Sensitivity Index. 
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Figure 3.: Evaluation of fasting IS indices in different subgroups. From left to right: total: 
whole population, NGT: normal glucose tolerant, NGT/age: NGT group divided by age 
(below and above median), IFG/IGT: all IFG or IGT subjects , D: diabetic subjects, 
D/HbA1c: all IFG/IGT/D subjects divided by HbA1c (%, below and above median), D/AIR: 
all IFG/IGT/D subjects  divided by beta cell function (acute insulin response = AIR), D/age: 
all IFG/IGT/D subjects divided by age (years, below and above median), gender: all subjects 
grouped by gender, BMI: all subjects divided by the existence of obesity (BMI < or  ≥30 kg x 
m
-2
). 
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Figure 4.: Evaluation of the OGTT indices in different groups. For abbreviations of each 
group see Figure 3.  
 
 
3.2. Clamp study on ALT – insulin sensitivity connections 
3.2.1. Study population 
 
General characteristics of the population are shown in Table 4. Mean HbA1c values 
were under 6.1% in all groups, i.e. the population consisted of either normal glucose tolerant 
or mostly prediabetic (IGT/IFG or fresh T2DM) subjects, both slightly overweight and obese 
individuals. Men tended to be younger and slightly more insulin sensitive than women in 
both the NGT and glucose intolerant (GI = IFG/IGT/T2DM) groups, although there were a 
lower prevalence of genetic predisposition in the NGT male group. The prevalence of genetic 
predisposition (the presence of diabetes in 1
st
 degree relatives vs. genetically non-predisposed 
groups) were between 20 and 40%, lowest in the male NGT group, as indicated. Significant 
differences were found between age and metabolic parameters in NGT vs. GI groups in both 
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genders as expected. ALT and GGT levels were higher in the GI vs. NGT groups in both 
sexes, AST levels differed significantly only in the male group between NGT and GI 
subjects.  
 
3.2.2. Associations between metabolic parameters, insulin sensitivity and liver 
function tests 
 
Simple bivariate and partial correlation coefficients are listed in Table 4. between 
liver enzymes (AST, ALT and GGT) and metabolic parameters (including M3, HIRI, blood 
sugar level, insulin secretion, lipids and adipocytokines), after correcting for age, BMI, 
alcohol consumption, HbA1c, abdominal circumference (and FSH in females). In males 
triglyceride, HDL-cholesterol, free fatty acid and Acute Insulin Response (AIR) show 
significant correlations with  ALT (and AST) after adjusting with the above confounding 
factors, while in females it is the clamp measured glucose uptake per se along with blood 
sugar values that stay significantly  related after correction is done (see on Table 4). GGT is 
rather non sex-specific, i.e. corrected associations with GGT show a similar pattern in both 
genders.  
Multiple regression analysis was carried out in order to determine the ability of the 
‘important’ attributes selected by Feature selection analysis (Boruta Algorithm, applied as a 
pre-regression analysis here) to predict clamp measured M3 values, separately in the male 
and female populations. The results in Table 6. show that F = 29.95 (p < 2.2e-16)  for women, 
indicating that the ‘important’ variables (BMI, AC, FFA, insulin and ALT) collectively have 
a significant effect on M3, ALT and BMI being significant independent predictors in women.  
In men (Table 7.) ‘important’ attributes (AC, leptin, BMI, insulin, TG, FFA, glucose, and 
diastolic blood pressure) have a significant effect on M3 [F = 14.71 (p < 2.36e-16)], serum 
leptin and insulin levels being independent predictors of clamp M3 values.  
The ability of the ‘important’ attributes to predict measured M3 is indicated in Figure 
5. for women, and in Figure 6. for men, where linear regression scatter plots for fitted vs. 
measured M3 values are shown. The regression model gave an excellent estimation of M3 in 
women, less so in men. 
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 NGT males(n=74) GI (IFG, IGT, T2DM) males(n=74) 
 mean±SD median MAD mean±SD median MAD 
Age (years) 33.43± 11.60 30.00 10.46 48.72±9.33** 51.40 7.75 
BMI (kg/m2) 26.66±5.01 25.10 2.42 29.99±4.30** 29.41 4.01 
Abdominal circumference(cm) 94.54± 13.11 90.50 6.67 105.07±14.55** 105.00 9.64 
HbA1C (%) 5.41± 0.43 5.40 0.44 5.90± 0.68** 5.80 0.59 
Fasting glucose (mmol/L) 4.89± 0.72 4.83 0.56 6.09±1.04** 5.96 0.96 
M3(mg/min/kg) 8.83±3.10 8.81 2.82 5.88±2.77** 5.74 2.38 
Hepatic insulin resistance index  54.42±33.06 48.86 24.98 63.86±33.84** 60.24 32.09 
Triglyceride (mmol/l) 1.46±1.14 1.07 0.55 2.65±2.18** 2.00 1.33 
HDL-C(mmol/L) 1.35±0.40 1.36 0.36 1.13±0.42** 1.08 0.29 
LDL-C(mmol/L) 2.48±0.83 2.31 0.80 3.00± 1.05** 3.03 0.79 
AST(U/L) 21.68±5.44 20.00 4.45 27.57±12.93** 25.00 8.90 
ALT(U/L) 24.81±10.56 22.00 7.41 36.24±26.98** 29.50 15.57 
GGT(U/L) 26.93±15.73 22.00 10.38 48.44±33.50** 39.00 28.17 
Alcohol (g/day) 0.09±0.38 0.00 0.00 0.30±0.67** 0.00 0.00 
Hypertension(%) 10.81 NA NA 43.24 NA NA 
Smoking(%) 14.86 NA NA 20.22 NA NA 
Genetic predisposition(%) 21.62 NA NA 32.89 NA NA 
 NGT females (n=47)        GI (IFG, IGT, T2DM) females(n=111) 
Age (years) 45.10±10.39 46.00 10.43 50.80±8.54** 53.00 7.41 
BMI (kg/m2) 26.85± 4.25 26.57 4.74 31.49±5.25** 31.57 4.96 
Abdominal circumference(cm) 91.95±12.18 92.00 14.08 104.42±12.49** 103.00 11.86 
HbA1C (%) 5.62± 0.50 5.60 0.59 6.06± 0.63** 6.02 0.62 
Fasting glucose (mmol/L) 5.08± 0.49 5.08 0.44 5.75±0.77** 5.65 0.76 
M3(mg/min/kg) 6.64± 3.24 6.29 2.79 4.36±2.08** 3.92 1.69 
Hepatic insulin resistance index 63.07±32.51 54.76 27.80 75.23±49.42** 60.77 36.46 
Triglyceride (mmol/l) 1.43±0.83 1.24 0.43 1.79± 0.81** 1.57 0.74 
HDL-C(mmol/L) 1.48±0.55 1.49 0.61 1.33±0.51 1.27 0.36 
LDL-C(mmol/L) 2.65±0.81 2.51 0.61 3.20±1.06** 3.17 0.87 
AST(U/L) 23.00±9.76 21.00 5.93 23.75±10.37 20.00 4.45 
ALT(U/L) 21.79±14.21 20.00 10.38 25.33±12.98* 22.00 8.90 
GGT(U/L) 25.95±28.13 19.00 11.86 31.76±25.29** 25.00 11.86 
Alcohol (g/day) 0.14±0.55 0.00 0.00 0.02±0.15 0.00 0.00 
Hypertension(%) 23.40 NA NA 43.24 NA NA 
Smoking(%) 14.86 NA NA 18.18 NA NA 
Genetic predisposition(%) 21.62 NA NA 36.36. NA NA 
 
 
 
Table 4. : Baseline biochemical and clinical characteristics of male and female 
populations. All values are means, medians and mean absolute deviation (MAD). NGT: 
normal glucose tolerant, GI= glucose intolerant, IFG=impaired fasting glucose, IGT=impaired 
glucose tolerant, T2DM= type 2 diabetes. M3: muscle mass adjusted glucose uptake. p<0.05*, 
p<0.01**, p<0.001***, p<0.0001**** 
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Table 5. 
Bivariate 
correlation
s adjusted 
for 
confoundin
g factors 
between 
metabolic 
parameters 
and liver 
enzymes in 
male and 
female 
subjects. 
Glu-0: 
fasting 
glucose, 
AIR: acute 
insulin 
response, 
FFA: free 
fatty acid, 
M3: muscle 
adjusted 
glucose 
uptake, 
HIRI: 
hepatic 
insulin 
sensitivity 
index. 
p<0.05*, 
p<0.01**, 
p<0.001***, 
p<0.0001**
**. 
Significant 
Partial 
correlations 
are 
indicated 
after 
adjustment 
for age, 
BMI, 
abdominal 
circumferen
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Coefficients:  Estimate     Std. Error   t value       Pr(>|t|)   
         (Intercept)   15.81509     1.22936     12.864      < 2e-16 *** 
             BMI        -0.23375       0.05272     -4.434        1.9e-05 *** 
             AC          - 0.01780       0.02081     -0.856        0.39377   
           Insulin       -0.04213    0.02469      -1.706          0.09028 .  
          IVFFA_0    -1.00410    0.56730      -1.770        0.07899 .  
             ALT        - 0.03159    0.01208      -2.616        0.00991 **  
 
 
Table 6: Multiple regression analysis for clamp M3 in women based on the ‘important’ 
attributes’ chosen by the feature selection analysis.  Signifiance codes: 0.0001 ‘***’ 0.001 ‘**’ 
0.01 ‘*’ 0.05. Residual standard error: 1.88 on 158 degrees of freedom. Multiple R-squared: 0.5259, 
adjusted R-squared: 0.5084, F-statistic: 29.95, p value: < 2.2e-16. . Significant independent 
predictors: BMI (***) and ALT (**). AC: abdominal circumference, IVFFA_0: 0
th
 minute FFA of the 
IVGTT.  
 
 
 
 
 
Figure 5: Linear regression for original versus fitted M3 values in women estimated by multiple 
regression analysis for attributes determined by feature selection. BMI (p=1.9e-05), AC (p= 
0.39377), serum-insulin (p= 0.09028), serum-FFA (p=0.07899), ALAT (p= 0.00991). Multiple R-
squared: 0.5259, Adjusted R-squared: 0.5084 
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Table 7: Multiple regression analysis for clamp M3 in men, based on the ‘important’ attributes 
chosen by the feature selection analysis. Significance codes: 0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05. 
Residual standard error: 2.331 on 148 degrees of freedom. Multiple R-squared: 0.4989, Adjusted R-
squared: 0.465, F-statistic: 14.71, p value: 2.368e-16. Significant predictors:  leptin (*) and insulin (*) 
levels. TG = triglyceride, AC:  abdominal circumferemce, IVFFA_0: basal FFA. 
 
Figure 6.: Linear regression for original vs. fitted M3 values in men estimated by multiple 
regression analysis for attributes determined by feature selection. AC (p= 0.2813), leptin (p= 
0.0294), BMI (p = 0.4253), serum insulin (p = 0.0210), triglyceride (p = 0.5699), serum-FFA 
(p=0.2364), serum-glucose (p = 0.1067), diastolic RR (p = 0.6340), age (p = 0.0516). Multiple R-
squared: 0.4989, Adjusted R-squared: 0.465. 
 
Coefficients: Estimate      Std. Error   t value     Pr(>|t|)   
(Intercept)    19.30144    2.35704      8.189    1.9e-13*** 
AC                 -0.03122    0.02886    -1.082     0.2813   
Leptin           -0.09451    0.04291    -2.202     0.0294 *  
BMI              -0.07101    0.08879    -0.800     0.4253   
Insulin          -0.09684    0.04147    -2.335     0.0210 *  
TG                 -0.07363    0.12927    -0.570     0.5699   
IVFFA_0      -0.69004    0.58016    -1.189     0.2364   
Glucose         -0.37848    0.23299     -1.624     0.1067   
RR_Dias       -0.01234    0.02586     -0.477     0.6340   
Age               -0.03591   0.01828     -1.964     0.0516 .  
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3.3. Epidemiologic association of metabolic syndrome, type 2 diabetes and bone 
loss in the adult population of Balaton Upper-lands 
 
3.3.1. Study population 
 
In our epidemiological database the results of 6282 screening tests were available, 
1561 men (mean age 56±13 years) and 4726 women (mean age 54±13 years). The baseline 
characteristics (age and gender) of the screened population are shown in Table 8. 
 
 
 
     Age groups (year)             Men (n)            Women (n) 
<40 163 (20.6%) 628 (79.4%) 
40–50 329 (22%) 1166 (78%) 
51–60 504 (27.2%) 1351 (72.8%) 
61–70 356 (26.33%) 996 (73.67%) 
>70 194 (26.5%) 538 (73.5%) 
 
Table 8.: Distribution of screened subjects based on gender and age. 
 
Based on the data that were available we have defined syndromes / diseases shown in Table 
9.  
 
 
  Diabetes :    presence of impaired glucose tolerance: fasting capillary plasma glucose >5.6 mmol/l        
and/or 2 hours capillary plasma glucose >7.8 mmol/l, any value  ≥11.1 mmol/l and / or 
known / treated  diabetes mellitus 
 
Hypertension:  untreated or treated known hypertension or  systolic blood pressure > 140 
                        And/or diastolic blood pressure  >90 Hgmm  
 
Overweight:   25<BMI<30,  obesity: BMI≥30,  severe obesity: BMI≥35 kg/m2 
 
Hypercholesterolemia:    total capillary plasma cholesterol >5.2 mmol/l  
 
Android obesity: Abdominal circumference: men >102 cm, women >88 cm 
  
Table 9.: Definitions of diseases / syndromes that were assessed 
 
 
Categories do not always mean definitive diagnoses as one time capillary plasma 
measurements may not enable us to adapt internationally used criteria systems although we 
have tried to define categories based on the valid international / national guidelines at the 
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time of the publication [27-31]. In case of “Metabolic syndrome” we have defined an ‘insulin 
resistant’ state not necessarily identical to the disease / syndrome defined by the ATP-III or 
WHO criteria (Table 10.).  
 
 
Metabolic syndrome:   Presence of DM/IGT/IFG, hypertension, hypercholesterolemia, 
obesity   and/or android obesity in overweight patient: the presence of 
at least 3 of these criteria at the same time.  
Osteoporosis:             T-score: <–2.5 and / or treated osteoporosis 
 
Osteopenia:                T-score: between  –1 and –2.5 
 
Table 10.: Definition of Metabolic syndrome, osteoporosis and osteopenia 
 
3.3.2. Results of epidemiologic data 
 
 
When assessing the correlations between bone density (T score) and some of the 
metabolic parameters (Table 11.) we found that there is a significant positive correlation 
between BMI and T score in every age group in women (except in women under the age of 
40), the correlation being strongest in the population > 70 years . This relationship was 
missing in men. Abdominal circumference shows a weak positive correlation with T score in 
women < 40 years  and in men between 40 and 50 years. Blood sugar showed significant 
positive association with T score only in men over 70 years.  
 
 
 BMI R=        Abdominal circumference R=        Blood sugar R= 
T score Men Women Men         Women Men Women 
<40 n.s. n.s. n.s.         +0.254** n.s. n.s. 
41–50 n.s. n.s +0.234*         +0.185** n.s. n.s. 
51–60 n.s. +0.115** n.s.         +0.152** n.s. n.s. 
61–70 n.s. +0.110* n.s.              n.s. n.s. n.s. 
>70 n.s. +0.230**** n.s.              n.s. +0.359****          n.s. 
 
Table 11.: Correlation coefficients of bivariate correlations measured between T score, BMI 
abdominal circumference and blood sugar levels within genders and age groups. Significant 
correlations are indicated:  *p<0.05, **p<0.02, ***p<0.01, ****p<0.001 
 
We have examined the prevalence of osteoporosis / osteopenia in patients with 
metabolic syndrome and diabetes based on gender and age groups. There was no significant 
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difference in the prevalence of decreased bone density between patients with metabolic 
syndrome and controls (those with no metabolic syndrome) in either gender or age groups. 
Looking at the frequency of osteoporosis / osteopenia in diabetic subjects we found that 
amongst 51-60 years old women the prevalence of osteopenia was significantly higher in the 
diabetic than in the normal glucose tolerant group (50 vs. 36.34% in diabetic vs. non-diabetic 
females, χ2: 5.237, p<0.022, OR: 1.711, 95% CI: 1.076–2.722). Mean age of the two groups 
(diabetic and normal glucose tolerant) was not significantly different (55.7±4.2 vs. 55.2±4.1 
years, p = 0.7), however the mean BMI in this diabetic group was significantly higher than in 
the normal glucose tolerant group (29.42±5.27 vs. 27.73±4.77, p<0.008)  which makes our 
data even stronger, as high BMI is generally accepted as a protective factor against bone loss. 
There was no significant difference in the prevalence of osteoporosis or osteopenia in other 
age groups in women or in any of the age groups in men between diabetic and control 
subjects. Due to high BMI having presumably both diabetogenic and osteoprotective role we 
have separately analyzed the prevalence of different stages of bone loss in normal weight 
diabetic (BMI < 25), normal weight non-diabetic, all diabetic and all non-diabetic subjects 
(Figure 8. and Figure 9.).  
 
Figure 8.: Prevalence of osteoporosis, osteopenia and normal BMD in normal weight 
(BMI<25) diabetic, normal weight non-diabetic, all non-diabetic and all non-diabetic 
subjects ≤ 60 years old. 
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Figure 9.:  Prevalence of osteoporosis, osteopenia and normal BMD in normal weight 
(BMI<25) diabetic, normal weight non-diabetic, all diabetic and all non-diabetic 
subjects > 60 years old. 
 
 
 
Considering the small sample size in each group, for statistical rationale we only defined 
two age groups, below 60 and over 60 years, and genders were not separately analyzed either. 
Within the individual age groups there was no difference between the mean age of the normal 
weight and all diabetic patients (53.8±10.0 vs. 56.4±8.6 and 70.6±6.4 vs. 69.4 ±5.9 years). 
We didn’t find significant difference in the prevalence of osteoporosis / osteopenia in the 
population under 60 years although there was a trend for increased prevalence of osteoporosis 
in normal weight diabetic versus all diabetic patients (Figure 8.). In the > 60 years group the 
frequency of osteoporosis was higher within the normal weight diabetic group than in all 
diabetic subjects, the difference being border significant with ‘osteoporosis’  (63.63 vs. 
26.2%, OR: 2.71, 95% CI: 0.969–7.6, p = 0.054) but only a trend was seen with ‘ostopenia’ 
(53.38 vs. 43.31%, p = 0.359), (Figure 9.).  There was no difference noted in the prevalence 
of osteoporosis / osteopenia in the all diabetic versus all non-diabetic group. (Figure 9.) 
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3.4. Clamp study; bone – energy homeostasis connections 
 
3.4.1. Study population 
 
After obtaining signed informed consent, we included 135 women (aged 49 ± 9 years) 
and 155 men (aged 42 ± 13) in our study. Subjects were classified based on results of a 
standard 75-g OGTT at screening (blood drawn at the 0, 30, 60, 90 and 120
th
 minute), 
according to ADA criteria [27]. We included 47 normal glucose-tolerant (NGT) and 89 
glucose-intolerant (GI: IFG and IGT and drug naïve T2DM) subjects in the female group; in 
the male group, there were 72 NGT and 83 GI subjects. The same inclusion and exclusion 
criteria were applied in this study as in the earlier clamp studies. 
 
3.4.2. Baseline characteristics 
 
General metabolic and other characteristics of male and female subjects in the study 
are summarized in Table 12. NGT and GI subjects are presented separately. Although OCN 
mean values were slightly higher in the NGT than in the GI groups in both genders, no 
significant difference was observed in OCN levels between NGT and GI subjects. In women 
this is the result of the effect of varying ages, that masks the positive association between 
OCN and glycemic state, in men however (see later) OCN is mainly associated with 
indicators of insulin sensitivity (i.e. glucose uptake rates and body composition) rather than 
with plasma glucose levels per se. OCN mean values were somewhat lower than described in 
healthy male and female population, although stayed in the normal range [32]. Subjects with 
extreme values were excluded from the study. Significantly higher total testosterone values 
were found in NGT than in GI males, while no such difference was observed between the 
respective female groups.  
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              Women             Men 
 NGT, n=47 GI, n=89  NGT, n=72      GI, n=83 
BMI(kg/m2) 27.1±5 31.6 ±5***   26.7 ±5.1 28.2 ±5.25*** 
Body Fat % 42.5 ±7.4 46.5 ±6** 26.8 ±7.98 28.7 ±8.11*** 
HbA1c (%) 5.84 ±0.8 6.06 ±0.6***   5.37 ±0.44 5.83 ±0.69*** 
OGTT glucose 0 min 5.1±0.45  6.1±0.83*** 5.01±0.45 6.32 ±0.89*** 
OGTT glucose AUC (mmol/l) 38.69 ±19.3 94.96 ±45.5*** 30.2 ±25.36 90.43 ±49.61*** 
OGTT insulin AUC (U/ml) 6627.3 
±4017 
8448 ±5617* 5402 ±3534 6796 ±4282* 
M1 (mg/min/BW kg) 
 
11.28 ±4.4 7.92 ±3.2*** 12.32 ±3.78 8.76 ±3.63*** 
M3 (mg/min/muscle kg) 
 
6.62±3.22 4.31±2.03*** 8.95±3.45   6.11±2.71*** 
Leptin (ng/ml) 27.8 ±22.7 31.94 ±20.8 10.13 ±9.89 8.72 ±6.63 
Adiponectin (µg/ml) 5.7 ±3.1 5.4 ±3.1 4.58 ±2.62 3.46 ±1.92 
Testosterone (ng/ml) 0.74 ± 0.84 ± 15.51±5.21    13.44 ±6.24* 
Osteocalcin (ng/ml) 18.89 ±7.49 18.13 ±7.66 19.87±8.27     19.08 ±9.15 
                 
 
Table 12.: General characteristics of the study subjects. OCN Normal range: 11–48 ng/ml 
for women, 14–46 ng/ml for men. Normal glucose-tolerant (NGT) and glucose-intolerant 
(GI) subjects, the latter consisting of impaired fasting glucose (IFG), impaired glucose-
tolerant (IGT), or drug-naive type 2 diabetic (2DM) subjects, are represented separately. 
Significant differences between NGT and IGT groups are shown. *p < 0.05, **p <0.01, 
***p<0.001. 
 
 
 
3.4.3. Metabolic associations of OCN in females 
 
Spearman's correlations and partial correlations between OCN and metabolic 
parameters of female subjects are shown in Table 13.  Significant association was observed 
between OCN and adiponectin levels independent of age, HbA1c, BMI and BFP. Higher 
OCN values were associated with increasing age in women. Significant correlation between 
OCN and improving metabolic state (lower OGTT glucose values, BMI, BFP, higher M1 and 
M3 levels) became apparent after the adjustment for age alone. Most of these associations 
ceased after further adjustment with HbA1c, BMI and BFP, except for fasting glucose. 
Further adjustment with adiponectin resulted in lost correlation between OCN and fasting 
glucose value, i.e. OCN effect on improving glycemic control might be partly mediated by 
adiponectin in females. Further adjustment was done with FSH levels in a subset of 68 
women (where FSH levels were available) in order to exclude the effect of menopausal state 
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on the metabolic associations of OCN (not represented in Table 13.). Positive associations 
between improved metabolic state and OCN became apparent after the adjustment with FSH, 
similar to the influence of age: R = −0.323, p = 0.0062 with HbA1c, R = −0.349, p = 0.0026 
with IVGTT glucose AUC, and R = −0.288, p = 0.0153 with OGTT glucose 0th min, R = 
+0.260, p = 0.031 with M3. As expected, a strong positive association was found between 
FSH levels and OCN, independent age, BMI, body composition and HbA1c values (R = 
+0.413, p = 0.00047). 
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OCN and: 
  
R= R = 
(adjusted for age) 
R=(adjusted for 
BMI, BFP, age and 
HbA1c)            
Cor   R=                    
(ad(adjusted for age, BMI, BFP,  HbA1c 
and  adiponectin) 
Age +0.231** - -  - 
HbA1c      n.s.    -0.267** - -           
OGTT glucose 0 min n.s. -0.236** n.s. n.s.                            
OGTT glucose 120 min                            n.s.        -0.205* n.s. n.s.        
OGTT glucose AUC n.s. n.s. n.s. n.s.                                  
OGTT insulin AUC n.s. n.s. n.s. n.s.                         
IVGTT glucose 0 min. n.s. -0.269** -0.190* n.s. 
IVGTT glucose AUC    n.s. -0.182* n.s. n.s.                           
IVGTT insulin AUC   n.s.  n.s. n.s. n.s.                           
AIR  n.s  n.s. n.s. n.s.                            
IGI    n.s.                n.s. n.s. n.s.                            
M1 n.s. +0.221** n.s. n.s. 
M3 n.s. +0.240** n.s. n.s. 
Leptin n.s. n.s. n.s. n.s.                           
Adiponectin +0.254** +0.254** +0.335***  -                        
Triglyceride n.s. n.s. n.s n.s.                           
Testosterone n.s. n.s. n.s. n.s.                           
BMI n.s. -0192* - - 
BFP n.s. -0.224** - - 
Waist circumference n.s. -0.212* n.s n.s. 
 
 
 
Table 13.: Bivariate (Spearman) and partial correlation coefficients adjusted for 
possible confounding factors (age, BMI, BFP and HbA1c), between OCN and metabolic 
parameters in women. When adjusted for age alone significant associations with metabolic 
parameters were disclosed, i.e. these were concealed due to age. When adiponectin was 
added for further adjustment as possible confounding factor, the significant association 
between fasting glucose and OCN ceased. The simple coefficients are shown in column 1, 
and partial correlation coefficients in columns 2–4. *p < 0.05, **p < 0.01, ***p < 0.001. n.s.: 
not significant; BMI: body mass index; BFP: body fat percent; OGTT: oral glucose tolerance 
test; AUC: area under the curve; IVGTT: intravenous glucose tolerance test; AIR: acute 
insulin response of the IVGTT.  IGI: insulogenic index of the IVGTT: (insulin 5 min − 
insulin 3 min) / (glucose 5 min − glucose 3 min). 
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3.4.4. Metabolic associations of OCN in males  
 
Spearman's and partial correlation coefficients between OCN and metabolic parameters in 
males are shown in Table 14.   
 
 OCN and R= 
 
R= 
(Adjusted for  
age,  
BMI, BFP 
 and HbA1c) 
R= 
(Adjusted for age, 
BMI, BFP, 
HbA1c and 
testosterone) 
R= 
(Adjusted for 
testosterone alone) 
 
Age 
 
n.s. 
 
- 
 
- 
 
n.s. 
 
HbA1c 
 
n.s. 
 
- 
 
- 
 
n.s. 
 
OGTT glucose 0.min 
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
 
 
OGTT glucose 120.min. 
 
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
OGTT glucose AUC n.s. n.s. n.s. n.s. 
OGTT insulin AUC 
 
-0.179* 
 
n.s. 
 
n.s. 
 
n.s. 
 
IVGTT glucose 0.min 
 
n.s. 
 
n.s. 
 
n.s 
. 
n.s. 
 
IVGTT glucose AUC 
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
 
IVGTT insulin AUC 
 
n.s. 
 
n.s 
 
n.s 
 
n.s 
 
AIR 
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
 
IGI n.s. n.s. n.s. n.s. 
M1 +0.229** n.s. n.s. +0.174* 
M3 
 
+0.221** 
 
n.s. 
 
n.s. 
 
n.s. 
 
Triglyceride 
 
-0.183* n.s. n.s. -0.178* 
Leptin -0.168* n.s. n.s. n.s. 
Adiponectin n.s. n.s. n.s. n.s. 
Testosterone +0.243** +0.193* - - 
BMI -0.199* - - n.s. 
BFP -0.172*                   -   - -0.171* 
Waist circumference -0.224**                   n.s. n.s. -0.221** 
 
 
Table 14: Spearman and partial correlation coefficients adjusted for possible 
confounding factors (age, BMI, BFP, HBA1c and testosterone), between OCN and 
metabolic parameters in men. When adjusted only for testosterone alone, significant 
association between muscle glucose uptake (M3) and OCN ceased, but stayed significant 
between M1 and OCN. The simple coefficients are shown in column 1, and partial 
correlation coefficients in columns 2–4. *p < 0.05, **p <0.01, ***p < 0.001. See list of 
abbreviations below Table 13. 
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The OCN levels were significantly associated with improving metabolic state 
(decreasing OGTT insulin AUC, leptin, BMI, BFP and increasing insulin sensitivity; i.e., M1 
and M3 values). These correlations disappeared after the adjustment for age, HBA1c, BMI 
and BFP. The significant positive correlation between OCN and testosterone levels was 
independent of age, HBA1c, BMI and BFP. After correction for testosterone alone, the 
significant positive association between OCN and M3, as well as the significant negative 
correlation with leptin and BMI was lost, i.e. metabolic associations of OCN were at least 
partly mediated by testosterone in males. 
 
3.4.5. Feature selection 
 
Feature selection (Boruta algorithm, Figure 10. and 11.) confirmed that age, IVGTT 
glucose 3, 5 and 60 minute values and adiponectin (mean Z: 9.76, 5.41, 4.09, 3.75 and 3.69, 
respectively) were the most important attributes in determining OCN levels in women. In 
men, M1, BMI, M3, leptin, BFP, OGTT 90
th
 min glucose and insulin values, in addition to 
testosterone (mean Z: 5.21, 4.95, 4.41, 4.04, 3.62, 3.57 and 3.54, respectively), but not 
adiponectin, were confirmed as the most important parameters independently associated with 
OCN amongst all metabolic factors examined. 
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Figure 10.: Feature selection analysis (Boruta method) to identify variables most closely 
related to OCN values in women. All IVGTT (0-60
th
 minutes: ‘IVGTTGlu- and Ins0-, 3-, 5-
, 10-, 15-, 20-, 30-, 40-, 50- and 60’) and OGTT (0-120th minutes: ‘OGTTGlu- and Ins0-, 30-, 
60-, 90- and 120’) glucose and insulin values, lipids [TG, total-cholesterol (total-chol)] and 
lipoprotein subfractions (total-LDL, total-HDL, IDL-A,- B,- and C, LDL1-4 subfractions), 
adipokines (leptin, adiponectin), anthropometric parameters (BMI, body fat percent [BFP], 
waist circumference [WC]), testosterone, systolic- and diastolic blood pressure (systBP, 
diastBP), acute insulin response (AIR), age, whole- and muscle glucose uptake (M1 and M3) 
values were ranked for OCN association. Age, IVGTT glucose 0-, 3-, and 5
th
 min values and 
adiponectin were confirmed as being ‘important’ attributes for OCN; these are represented as 
green columns. Yellow and red columns represent attributes that were ‘rejected’ or ‘tentative’ 
as being important variables for OCN. Blue columns represent ‘shadow attributes’. The Y 
axis represents the value of importance (mean, median, minimum, and maximum Z).  
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Figure 11.:  Feature selection analysis (Boruta algorithm) to identify variables most 
closely related to OCN values in men. All IVGTT (0-60. minutes: ‘IVGTTGlu- and Ins0-, 
3-, 5-, 10-, 15-, 20-, 30-, 40-, 50- and 60’) and OGTT (0-120. minutes: ‘OGTTGlu- and Ins0-, 
30-, 60-, 90- and 120) glucose and insulin values, lipids [TG, total-cholesterol (total-chol)] 
and lipoprotein subfractions (total-LDL, total-HDL, IDL-A,- B,- and C, LDL1-4 
subfractions), adipokines (leptin, adiponectin), anthropometric parameters (BMI, body fat 
percent [BFP], waist circumference [WC]), testosterone, systolic- and diastolic blood 
pressure (systBP, diastBP), acute insulin response (AIR), age, whole- and muscle glucose 
uptake (M1 and M3) values were ranked for OCN association. M1, BMI, M3, leptin, BFP, 
90-minute glucose and insulin of the OGTT and testosterone were confirmed as ‘important’ 
attributes for OCN; these are represented as green columns. Yellow and red columns 
represent attributes that were rejected or ‘tentative’ for being important attributes for OCN. 
Blue columns represent ‘shadow attributes’. The Y axis represents the value of importance 
(Z), (mean, median, minimum, and maximum).  
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Discussion  
 
4.1.  Evaluation of simple indices in the estimation of clamp measured insulin 
sensitivity 
 
Quantitative determination of IS and/or beta cell function (BCF) has a great 
significance when studying metabolic diseases, i.e. the relationship between bone metabolism 
and energy homeostasis. Although, a number of indices have been developed earlier [22], the 
comparison between the simplest fasting HOMA and clamp indices show a quite 
heterogeneous picture, there are those reporting about strong [33], week [34] and non-
significant [18] results. Strong correlation was found between clamp index and HOMA-R in 
young or middle-aged NGT subjects, or in smaller studies with T2DM patients [33, 35-37]. 
QUICKI, the logarithmic transformation of HOMA, improved the correlation in a small, 
heterogeneous population (r = 0.78 vs. 0.6) [21]. No significant correlation was found 
between either HOMA, or QUICKI and clamp indices in other reports in elderly, poorly 
controlled diabetic populations [38].  
In our study, which included drug-naïve prediabetic or normal glucose tolerant 
subjects with a wide range of insulin resistance, the correlation were moderate (r = 0.4-0.6) 
between HOMA and clamp measured glucose uptake in most groups. We found weaker 
correlations in the NGT and in the glucose intolerant groups with higher age (above median). 
Correlations between fasting and clamp indices were weaker in the IGT group with lower 
HbA1c and higher AIR (i.e. less severe metabolic state) than in IGT subjects with higher 
HbA1c and lower AIR (i.e. more decreased beta cell function). According to our results the 
utility of HOMA-S% (Oxford Model) was far behind the expected, although today it is 
considered the most accepted, best fasting index [39,40]. Correlations between QUICKI and 
M was not improved by FFA in our study which is in contrast with previous results [24].  
Amongst OGTT indices we compared the values of the five most often used indices 
based on empiric equations validated by clamp [16-19]. An independent study used 
discrepancy index (DI) to compare several OGTT indices, which showed that MCRest and 
OGIS adjusted for body weight are structurally the closest indices to clamp, i.e. these two 
least under- or overestimated the correlations between basic parameters (Ins0 ,Glu0, BMI, 
Glumean, Glu120) and M1 [41]. In our study we found that the three OGTT indices including 
body weight or BMI in their equations, MCRest, ISIest and ISICederholm showed the best 
correlation with clamp M1, as expected in a population with wide range of BMI. Based on 
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the correlations measured within the different groups, the cumulative scores approached 90%. 
We conclude that in this mostly overweight population with varying glucose tolerance, 
including BMI/weight into the equation improves its value compared to indices based only on 
glucose and insulin values. Another advantage of OGTT indices is that they show a fairly 
homogeneous value in most examined groups, except in elderly NGT subjects, where their 
value was decreased, similar to fasting indices. Individual diagnostic values of the HOMA 
and OGTT based IS models may still be a matter of debate, since the best sensitivity for IR 
diagnosis was only 50% for fasting and 67% for OGTT indices. The lower sensitivity of 
HOMA versus OGTT indices is shown in a study where OGTT insulin area under the curve 
(AUC) indicated IR in 44%, while HOMA-R only 18% of 49 normal weight women with 
polycystic ovary syndrome [42]. A gender (and racial) difference in the utility of insulin-
based fasting and OGTT-based models has recently been described, as both gender and race, 
had a significant effect on explaining the predictability of clamp-measured glucose disposal 
rates [43]. Although we did not find significant difference between genders in the value of 
either fasting or OGTT indices and could not assess the effect of race as all subjects were 
Caucasian in our study, we did find some basic gender difference when the associations 
between liver enzymes and insulin sensitivity were analyzed. 
4.2. ALT – a possible simple indicator of insulin sensitivity in women 
 
One of the most important findings of our study in this healthy / prediabetic 
population is that after the adjustment for confounding factors such as age, BMI, abdominal 
circumference, body fat percent, HbA1c, alcohol consumption (and FSH levels in women), 
all three liver enzymes (ALT, AST and GGT) stayed significantly associated with clamp-
measured insulin sensitivity (i.e. muscle glucose uptake) in women but disappeared in men. 
This difference was only applicable for the gold standard clamp measured peripheral insulin 
sensitivity, i.e. the association with the estimated OGTT derived Hepatic Insulin Resistance 
Index (although stronger in females than in males) disappeared in both genders after the 
correction was done (Table 5.). Moreover, the multiple regression model has found that ALT 
was a significant independent predictor of clamp insulin sensitivity besides BMI in females. 
In men, this was fasting insulin and leptin but none of the transaminase levels. Lee et al. 
described a similar gender difference in a study on adolescent population: obesity and 
triglyceride were the major determinants of HOMA-IR in boys, and obesity and GGT in girls, 
so liver function test (i.e. transaminase level) only predicted insulin resistance measured by 
HOMA model in females [44]. Furthermore, the independent association with IR and ALT 
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was stronger in girls than in boys (p = 0.034 vs. p = 0.005) [44], albeit the latter result was 
not confirmed by clamp studies. Those studies having found an independent association 
between ALT and directly (clamp or minimal model analysis) measured insulin sensitivity 
were carried out on mixed-gender populations (either healthy prediabetic or IGT subjects), 
although results stayed significant after the adjustment for sex and other confounding factors 
[45, 46].  
Our results support the hypothesis that a very delicate sex difference exists in the 
progression / association of NAFLD with metabolic parameters in the adult population and 
this has an important clinical implication. In women, it is clearly evident that insulin 
resistance per se might indicate liver fat accumulation, and vice versa, elevated ALT levels 
might indicate decreased insulin sensitivity earlier than fasting insulin, lipoprotein or 
adipokine levels. In men, ALT (also AST and GGT) elevations coexist with other metabolic 
changes followed / caused by insulin resistance. Therefore liver enzyme elevation per se is 
not an indicator of decreased insulin sensitivity but a general metabolic deterioration along 
with insulin resistance in men, with no independent associations with the clamp M3 value. 
The obvious sex difference in fat distribution leads to increased susceptibility to intra-
abdominal, visceral and liver fat accumulation in men, which is at least partially driven by 
differential sex hormone settings [47]. A further explanation and/or consequence is the sexual 
dimorphism displayed by liver-associated markers, such as sex hormone-binding globulin 
(SHBG) and adiponectin levels being much lower in men, consistent with their greater 
insulin resistance and greater risk of diabetes and cardiovascular disease at a younger age [48, 
49] and the more severe metabolic phenotype at the diagnosis of NAFLD [50]. This is in 
agreement with the finding of Feitosa et al., that ALT is a significant independent predictor of 
coronary heart disease in men but not in women, with the association being stronger in non-
diabetic men [51]. 
Based on the above results slightly elevated ALT may strongly indicate the presence 
of insulin resistance in females even without hyperinsulinemia, especially in overweight 
women. Hence, the use of ALT in estimating clamp measured insulin sensitivity might be  
more relevant in females, while that of fasting insulin-based indices (i.e. the HOMA model) 
physiologically seems to be more appropriate in males according to our results. A future 
direction could be to include transaminase levels within the HOMA index, which may 
increase the diagnostic value of the HOMA model, especially in females (correlations with 
HOMA-S in all females is improved by including ALT into the equation in women: R = 
0.495 vs. R = 0.588, non-published data). As a conclusion we found that: 1. Conventional 
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fasting IS indices only correlate moderately with the clamp results,  2. OGTT derived IS 
indices correlate well with the clamp data so whenever it is possible they should be used 
instead of the less precise fasting indices, 3. Liver transaminase levels may increase the 
diagnostic value of the conventional fasting indices, especially in females, and as such they 
always should to be considered to be a useful tool for IR diagnosis as part of the routine 
laboratory assessments, either with or without HOMA  model.  Moreover, we must take this 
into consideration when trying to interpret unexplained transaminase elevation, especially in 
female patients. 
 
 
4.3. Bone – energy homeostasis axis 
 
4.3.1. Discussion of epidemiologic data 
 
Numerous studies have been published about the bone effects of diabetes, most of 
these show higher BMD in T2DM [52-54] and lower in T1DM patients [52, 55, 56]. Diabetes 
is and independent risk factor for osteoporosis and bone fracture in the elderly normal weight 
women [57]. Patients suffering from T2DM initially even with higher BMD seem to have an 
accelerated bone loss and increased risk of bone fracture [58]. In most of the studies the 
favorable effect of T2DM on BMD and osteoporosis is decreased or ceased if data are 
adjusted with BMI, suggesting that the protective effect of diabetes is via increased body 
weight. This finding has been confirmed in our study as based on our results the increased 
BMD in T2DM is primarily due to increased BMI; diabetes per se is rather increases the risk 
of than protects against osteoporosis. 
Less results are available about gender differences, studies done in this field have 
found that the positive correlation between T2DM and bone density is weaker or lacking in 
men, furthermore the positive association between hyperinsulinemia and BMD appears to be 
stronger in women than in men [52, 54, 59, 60]. Our preliminary clamp studies have 
confirmed that during the initial stages of impaired carbohydrate tolerance the whole body 
glucose utilization rate (which is the gold standard method of insulin sensitivity) shows a 
significant association with bone density only in females [61].  The results of our screening 
tests showed that blood sugar level has a significant correlation with bone density only in 
elderly males and the classic positive correlation between BMI and BMD was only 
demonstrated in females. We found that in women in their early postmenopausal age 
(between 50 – 60 years) osteopenia was significantly more frequent than in the normal 
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glucose tolerant group despite the significantly increased BMI, although no difference was 
observed in the prevalence of osteoporosis.  
In conclusion our results have confirmed findings which show that T2DM (similar to 
T1DM) increases the frequency of osteopenia and osteoporosis in certain populations (like 
postmenopausal women and normal weight diabetic patients), furthermore the increased 
BMD generally found in T2DM is a consequence of increased body mass index as such 
diabetes can be considered rather risk increasing than protective factor. Our results have also 
drawn the attention to the notion that basic gender differences may exist in the bone – energy 
homeostasis relationship.   
 
 
4.3.2.  The role of OCN; gender difference in the bone – energy homeostasis 
relationship 
 
4.3.2.1. OCN and adiponectin 
 
Between 2005 and 2010 we have measured non-carboxylated OCN levels of all either 
normal or impaired glucose tolerant subjects, or drug naïve type 2 diabetic patients who 
underwent a hyperglycemic normoglycemic clamp to measure their insulin sensitivity. OCN 
is believed to be one of the most important neurohumoral link between bone and energy 
homeostasis and as such measuring total OCN levels in patients with known insulin 
sensitivity in a wide range of different levels of glucose tolerance may give us important 
clues about the pathophysiologic background of diabetes induced bone loss and causes of 
possible gender differences. In our preliminary clamp studies we have first shown on human 
data that OCN shows a positive correlation with insulin sensitivity [62], furthermore we have 
also described the existence of a basic gender difference in the relationship of insulin 
sensitivity with bone functional metabolic unit derived from the ratio of bone formation 
(osteoprotegerin (OPG), procollagen type 1 N-terminal propeptide (P1NP)) and resorption 
markers (cathepsin-k, soluble receptor activator NF-kB ligand (RANKL) and β-crosslaps) 
[63].  
A putative feed-forward regulatory loop ties bone turnover to energy regulation as 
proposed by Ferron et al. and Fulzele et al. in 2010 [64, 65]. Insulin activates skeletal 
remodeling (that is, increases bone formation by osteoblasts and resorption by osteoclasts), 
which in turn releases uncarboxylated osteocalcin from the skeletal matrix into the 
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circulation. This enhances insulin secretion and increases the insulin sensitivity of adipocytes. 
Based on the findings of Lee et al. OCN also increases insulin sensitivity by stimulating the 
secretion of adiponectin besides having a direct hypoglycemic effect via its secretagogue 
function on pancreatic beta cells [66].  We have found that even following the adjustment by 
confounding factors, higher OCN values were associated with higher adiponectin levels in 
female subjects (Table 2), similar to earlier studies [4, 10]. The same association was not 
found in male subjects. This is in accordance with the study of Kanazawa et al. who found a 
significant positive association of serum osteocalcin and adiponectin levels only in 
postmenopausal women, but not in men [67]. The authors suggested that the difference in 
adiponectin levels within sexes may have contributed to these findings but no further 
assessments were done to explore the possible rationale behind. In contrast it was also 
reported by others that the inverse relationship between carboxylated OCN and adiponectin is 
independent of gender and stays significant after correction with BMI [68]. Our study 
confirms the association of serum OCN with improved metabolic state (i.e. increased insulin 
sensitivity and glycemic control) but based on our findings the mechanism of action may 
differ significantly between sexes. 
 
 
4.3.2.2. OCN in postmenopausal women 
 
Bone turnover is accelerated with increasing age, especially in women [69, 70], which 
may be the reason for elevated serum OCN levels with higher age found both genders [71]. 
Our results confirmed that higher OCN was indeed associated with increasing age and FSH 
levels in female but not in male subjects. The significant positive correlation between OCN 
and improved metabolic parameters were only found after the correction for age and FSH, i.e. 
higher OCN levels due to increased bone turnover with increasing age and insulin resistance 
would mask its ‘true’ metabolic character. After further adjustment with body composition 
and HbA1c in addition to age, most of the significant correlations between OCN and 
metabolic parameters decreased or disappeared entirely, except for fasting glucose. Further 
adjustment with adiponectin resulted in lost correlation between OCN and fasting glucose, 
which supports the mediating role of adiponectin in some but not all of the metabolic effects 
of OCN in females. These findings disagree with recent data from Hwang et al. [9], who 
found that although serum OCN levels were indeed associated with improved glucose 
tolerance, beta cell function and OGTT measured insulin sensitivity, these were independent 
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of the plasma adiponectin levels. However, their data were derived from a mixed-gender 
population. According to our results the positive metabolic effect of OCN in women is not 
related to pancreatic beta cell function (as no correlation was found with AIR) but rather to 
adiponectin. In fact, the adiponectin mediated insulin sensitization pathways first confirmed 
in mice [66] were at least partly confirmed in women by our findings.  
 
4.3.2.3. OCN in men 
 
In contrast to female subjects, no sign of an ‘OCN–adiponectin axis’ was detected in 
men; i.e. no correlation was found between adiponectin and serum OCN level albeit the 
expected strong independent association with improved insulin sensitivity was indeed 
present. Recently, it was demonstrated that osteoblasts may induce testosterone production by 
the testes, although ovarian estrogen production in females is unaffected. Analysis of cell-
specific loss- and gain-of-function models has revealed that OCN performs this endocrine 
function by binding to a G protein-coupled receptor expressed in Leydig cells, and OCN 
regulates the expression of enzymes required for testosterone synthesis in an cAMP response 
element-binding protein-dependent manner, thus promoting germ cell survival [12]. On the 
other hand, meta-analysis of cross-sectional data suggests that the metabolic syndrome is 
associated with male hypogonadism / hypotestosteronemia [72]. The same association was 
not confirmed in females [13]. Our results show that adiponectin is not associated with OCN 
levels in male subjects; however, increasing OCN levels were indeed associated with higher 
testosterone values, independent of age, weight, adiposity and HbA1c. When data were 
adjusted for testosterone levels, some of the significant correlation between OCN and insulin 
sensitivity, leptin and BMI disappeared. Correlations with whole body glucose utilization, 
BFP, waist circumference, and triglyceride values were not affected. These results might 
suggest a partial role of testosterone in the metabolic connections of OCN in males, although 
because these data were cross-sectional, the cause–causality relationship needs to be further 
clarified.  
4.3.2.4. Lessons learned from feature selection analysis 
 
Feature selection analysis clearly describes the gender difference: in women, OCN is 
independently associated with adiponectin, age, and three of the IVGTT glucose values; 
while in men, it is associated with testosterone, BMI, BFP, M1 and M3, OGTT 90
th
 minute 
insulin and glucose, and leptin levels. Thus, an ‘OCN–adiponectin–glycemic state axis’ 
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versus ‘OCN–testosterone–insulin resistance axis’ may exist in women versus men, 
according to our data. The sex difference might be partially explained by the difference in 
adiponectin concentration, as adiponectin levels are significantly higher in women at all 
levels of glucose tolerance (normal, prediabetes and type 2 diabetes) than in men [73]. The 
fact that several papers have confirmed the positive association between serum OCN and 
adiponectin in postmenopausal women [74, 75] but not in men [4, 67] supports the notion 
that  OCN stimulates the expression of adiponectin only in female adipocytes in humans. In 
an earlier study, testosterone treatment reduced plasma adiponectin concentration in male 
mice, whereas testosterone also reduced adiponectin secretion in adipocytes [76]. It is 
therefore plausible to assume that high testosterone levels counteract with OCN in 
stimulating the expression of adiponectin in adipocytes in men. This could explain why we 
(and others) did not find any association between OCN and adiponectin in men. Furthermore, 
recently a large cross-over study has shown that adiponectin is inversely and independently 
associated with bone mass only in women but not in men [77] which result also underlines 
the importance of adiponectin in female over male bone physiology. The fact that in men 
OCN still has the earlier described positive associations with metabolic parameters proves 
that adiponectin independent pathways may indeed play a role in the male bone–energy 
homeostasis. Testosterone can only be partially responsible as our results have also 
confirmed this notion. Moreover, lower testosterone levels indeed coincide with worsening 
metabolic state with decreasing OCN, and this could alone explain numerous observations 
that may interfere with the interpretations of our results. Further longitudinal studies are 
needed to determine the real nature of the OCN–testosterone axis, particularly its long term 
effect on metabolic state of men.  
Further data analysis of our clamp studies have shown that basic gender differences 
exist in other neurohumoral links of the bone – energy homeostasis relationship, i.e. the 
OPG/RANKL system which besides being important regulators of the bone resorption / 
formation cycle, have also been associated diabetes severity, diabetic micro- and 
macrovascular complications, including acute cardiovascular mortality and morbidity [78, 79, 
80]. We have recently shown that while osteoprotegerin (OPG) seemed to be an indicator of 
the presence of small-dense LDL subfractions (LDL-2-5) along with decreased presence of 
the ‘normal’ large buoyant (LDL-1) subfraction fenotype in women, a positive association 
with clamp measured insulin sensitivity was shown only in men, with no clinically relevant 
associations with lipid subfractions [81]. 
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 The significance of this finding is still unclear, although it draws the attention to the 
gender specific nature of the association between bone turnover markers and metabolic 
diseases. Since the OPG/RANKL system is deeply involved in the OCN – insulin 
homeostasis axis by regulating bone resorption and so providing the acidic environment in 
the resorption pit for OCN undercarboxylation which results in the production of functionally 
active, i.e. ‘undercarboxylated’ OCN, it is plausible to presume that the OPG/RANKL system 
has an important role in the metabolic functions of OCN although this needs to be further 
assessed by in vitro / in vivo / observational and clinical studies. 
 
4.4. Limitations of our study 
 
Our study has several limitations. First, based on its cross sectional study design, the 
present findings are inherently limited in the ability to eliminate causal relationships between 
the investigated metabolic / bone parameters / liver markers and insulin resistance or 
sensitivity. Total instead of undercarboxylated OCN values were measured which latter is the 
metabolically active form of OCN. Some of the discrepancies found between our results and 
earlier data might have been resulted from this (i.e. lack of relationship between serum OCN 
and parameters of insulin secretion, like AIR or IGI of IVGTT), at least in part. We measured 
total instead of free testosterone levels, which is the bioavailable form of testosterone, 
although its metabolic role was indeed proven by large scale studies using both total and free 
testosterone measurements. The population we investigated involved both diabetic as well as 
non-diabetic subjects, both pre- and postmenopausal women although appropriate 
adjustments were made for confounding factors such as HbA1c, body composition, age or 
FSH.  Since some of the study population had several risk factors, including hypertension, 
and dyslipidemia, we could not eliminate the possible confounding effect of underlying 
diseases on the findings, although the prevalence of controlled hypertension, smoking and 
dyslipidemia were similar throughout the male and female groups in our study population.  
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5. Summary of new observations and future implications 
 
Between 2005 and 2010 we have carried out approximately 300 hyperinsulinemic 
normoglycemic clamp tests mostly on normal glucose tolerant and prediabetic subjects also 
including drug naïve type 2 diabetic patients at the time of the clamp. Our major purpose was 
to find metabolic associations in this patient population that would help us to identify 
potential subjects who later develop insulin resistance and type 2 diabetes and find clinical 
characteristics that would accompany insulin resistance although not necessarily being 
essential part of the ‘insulin resistance syndrome’. At first we have assessed the diagnostic 
value of simple fasting and OGTT derived insulin sensitivity indices on normal and impaired 
glucose tolerant (prediabetic) population and we found that the HOMA model used to 
diagnose insulin resistance in the everyday clinical practice does not precisely predict clamp 
measured insulin sensitivity especially in the elder populations. OGTT derived insulin 
sensitivity indices may be better alternative, because of the need for serial insulin 
measurements the cost of such investigations however may be high. In Hungary this was the 
first large sample sized clamp study which specifically addressed this issue. Using simple 
liver function test (like ALT) to improve the value of the HOMA model might be helpful, 
albeit because of the gender specific nature  of  the aethiopathogenesis of IR driven 
steatohepatosis described by us first in detail, it can only be a valuable approach in women 
according to our findings.  
The results of a large sample sized epidemiologic study in ‘Balaton Upper-land’ 
carried out by us between 2005 and 2007 including more than 6000 subjects, drew our 
attention to the ‘Janus faced’ nature of the relationship between type 2 diabetes and bone 
metabolism, i.e. although higher BMI predicts higher BMD values, there is still an increasing 
prevalence of osteoporosis and osteopenia on certain diabetic / prediabetic populations, like 
normal weight diabetic subjects. Moreover, we have found important data about a possible 
gender difference in this respect which was also confirmed by our preliminary clamp data.  
We have measured non-carboxylated OCN in all prediabetic patients who underwent a 
hyperinsulinemic clamp study to assess the association between metabolic data including 
clamp measured insulin sensitivity and OCN values which believed to be the most important 
link in the bone – energy homeostasis axis. We have proved that  an ‘OCN–adiponectin–
glycemic state axis’ versus ‘OCN–testosterone–insulin resistance axis’ exist in women versus 
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men which draws the attention to the gender specific nature of the bone – energy homeostasis 
association but also gave insight to the potential mode of actions OCN may have on insulin 
and glucose metabolism.  
Future directions include gender specific approach in insulin resistance studies, 
including the assessment of bone specific biomarkers like OCN, OPG and RANKL, their 
possible role in interventions to prevent or predict insulin resistance / type 2 diabetes and 
complications. Furthermore, studying gut microbiome in relation to bone metabolism, which 
is the collective metagenomic character of the overall bacterial composition of the gut 
(microbiota) in prediabetic state may be a promising new direction, since microbiota may be 
an important etiological factor and a possible promising therapeutic target for T2DM (and 
T1DM) [82], however only very few data exist about the association of microbiome and bone 
metabolism, mostly in preclinical models [83]. Moreover besides genetic, epigenetic studies 
are also being urged to identify possible markers of the prediabetic state, and type 2 diabetes 
[84]. Most importantly to find biomarkers and other characteristics in the juvenile / 
adolescent population in long term follow-up observational / epidemiologic studies that 
predict the parallel development of type 2 diabetes and bone loss later in life which could 
possibly make the development of these diseases / symptoms preventable. Systems medicine 
is a promising tool to identify factors that play a role in the etiology, disease progression and 
the success of therapeutic interventions of insulin resistance and type 2 diabetes [85]. 
Discovering more sides of the bone – energy homeostasis by using systems medicine will 
enable us to understand clinically meaningful associations that would help us to prevent 
diabetes linked bone loss, which would have a great impact on the diagnosis and prevention 
of the two most burdening diseases in today’s health care. 
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